In the clinic, in vivo activity of CYP enzymes is most commonly predicted from an individual’s genotype, which underestimates the potential effects of a host of other factors, including inhibition of CYP expression and activity by increased levels of circulating inflammatory cytokines during chemotherapy for breast cancer. This evidence concerns the gene PPIG and breast cancer.